Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Diffuse Large B-Cell Lymphoma (DLBCL)”

691 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 691 results

Testing effectiveness (Phase 2)UnknownNCT04796857
What this trial is testing

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Who this might be right for
Non-GCB/ABC Diffuse Large B-Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIb+3 more
Huiqiang Huang 30
Testing effectiveness (Phase 2)UnknownNCT05875428
What this trial is testing

Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 104
Testing effectiveness (Phase 2)Looking for participantsNCT07473167
What this trial is testing

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Who this might be right for
Relapsed Large B-cell LymphomaRefractory Large B-cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)+3 more
TICAROS Co., Ltd. 98
Testing effectiveness (Phase 2)Study completedNCT01741792
What this trial is testing

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
Amgen Research (Munich) GmbH 25
Early research (Phase 1)Looking for participantsNCT06977711
What this trial is testing

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
The University of Texas Health Science Center at San Antonio 10
Large-scale testing (Phase 3)UnknownNCT04789434
What this trial is testing

PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

Who this might be right for
Lymphoma, Large B-Cell, DiffuseTransplantationChemotherapy
Ruijin Hospital 94
Early research (Phase 1)Study completedNCT00655837
What this trial is testing

Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

Who this might be right for
Lymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
Seagen Inc. 33
Early research (Phase 1)Study completedNCT02142530
What this trial is testing

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

Who this might be right for
Non-Hodgkin LymphomaDiffuse Large B-cell LymphomaMantle Cell Lymphoma+2 more
Massachusetts General Hospital 19
Testing effectiveness (Phase 2)UnknownNCT03367143
What this trial is testing

Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL

Who this might be right for
Diffuse Large B-Cell Lymphoma Refractory
Ruijin Hospital 39
Early research (Phase 1)UnknownNCT05039658
What this trial is testing

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

Who this might be right for
DLBCL
Innovent Biologics (Suzhou) Co. Ltd. 50
Testing effectiveness (Phase 2)UnknownNCT02737085
What this trial is testing

The Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
Southwest Hospital, China 40
Large-scale testing (Phase 3)Study completedNCT01459887
What this trial is testing

Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma
Shanghai CP Guojian Pharmaceutical Co., Ltd. 278
Testing effectiveness (Phase 2)Ended earlyNCT05319028
What this trial is testing

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Non-GCB/ABC Diffuse Large B-Cell LymphomaWith and Without MyD88 and/or CD79B Mutations
Calithera Biosciences, Inc 2
Testing effectiveness (Phase 2)Looking for participantsNCT06758037
What this trial is testing

Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy

Who this might be right for
DLBCLDiffuse Large B-Cell Lymphoma
First Affiliated Hospital of Ningbo University 50
Testing effectiveness (Phase 2)UnknownNCT01670370
What this trial is testing

Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.

Who this might be right for
Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University 60
Testing effectiveness (Phase 2)UnknownNCT04425824
What this trial is testing

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell LymphomaRituximabToripalimab
Chinese Academy of Medical Sciences 20
Testing effectiveness (Phase 2)Study completedNCT00799513
What this trial is testing

Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
IRCCS San Raffaele 48
Post-approval studies (Phase 4)UnknownNCT02752815
What this trial is testing

Reduced Chemotherapy in Low Risk DLBCL

Who this might be right for
Diffuse Large B-cell Lymphoma
Ruijin Hospital 290
Testing effectiveness (Phase 2)Ended earlyNCT02488512
What this trial is testing

Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas

Who this might be right for
DLBCLMCLRecurrent Disease
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 1
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07034508
What this trial is testing

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Who this might be right for
DLBCL - Diffuse Large B Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 134
Load More Results